Search Results for “EC” – Page 332 – media

In Cardiology, AI Enables Me to Deploy Therapy Faster, and Can Make the Difference Between Life and Death

I work as a cardiologist for a multi-specialty group that sees patients both in capitated payer and fee-for-service environments. This diverse practice gives me the experience to know where insurance providers will find value or what they will likely pay for. As these protocols become more scientifically validated, AI is going to help the entire healthcare system to identify at-risk patients quickly and accurately. By DR. JONATHAN A. ALIOTA As a cardiologist, I see this kind of scenario play out on a daily basis. A patient comes in for a routine procedure and a heart murmur is detected. This murmur could have several different diagnoses. While they can be a sign of something more serious, many of the heart murmurs we hear on a routine basis are normal, physiologic murmurs, such as mild mitral regurgitation. In addition, a healthy heart that had too much caffeine and not enough water that ...
- Source: drugdu
- 97
- November 28, 2023
AWS, Hoppr Launch Model to Accelerate Generative AI Tools in Medical Imaging

At RSNA 2023, AI startup Hoppr announced that it teamed up with AWS to launch a new foundation model. The product, named Grace, is a B2B model designed to help application developers build better AI solutions for the medical imaging field — and to build them more quickly. By KATIE ADAMS AI startup Hoppr teamed up with AWS to launch a new foundation model to help bring more generative AI solutions into medical imaging, the companies announced on Sunday at RSNA 2023, the annual radiology and medical imaging conference in Chicago. The new product, named Grace, is a B2B model designed to help application developers build better AI solutions for medical images — and to build them more quickly. Along with the launch of Grace, Hoppr also announced that it received “a multi-million dollar investment” from Health2047, the American Medical Association’s venture studio. Chicago-based Hoppr, which was founded in 2019, ...
- Source: drugdu
- 117
- November 28, 2023
Novo Nordisk announces $2.3bn investment to expand production site in France

Novo Nordisk has said it will be investing more than $2.3bn to expand its existing production site in France “for the current and future product portfolio within serious chronic diseases”. The investment will “significantly increase” the capacity of the Chartres manufacturing facility, Novo said, including for its GLP-1 products in the cardiometabolic disease space. The site in Chartres was first established in 1961 and currently employs around 1,600 people, with more than 500 new jobs expected to be created as a result of the expansion. Lone Charlotte Larsen, corporate vice president of Novo Nordisk Production Chartres, said: “This significant investment… confirms the importance of our French manufacturing site, one of our strategic production sites, as a cornerstone of the growth we are experiencing as a company. “By maximising the skills and infrastructure we already have on the site, we are expanding our capacity in an efficient way.” The expansion is ...
- Source: drugdu
- 100
- November 28, 2023
Novo Nordisk expands site to manufacture GLP-1 drugs

Novo Nordisk announced plans to expand one of its production facilities in Chartres, France, as it scales up its serious chronic disease product portfolio. Under the Dkr16bn ($2.29bn) investment, Novo Nordisk is increasing the capacity of the manufacturing site by extending the current quality control laboratory, adding aseptic production, and finishing production processes. The company predicts that this will bring over 500 new jobs once construction is completed. According to the press release, the investment includes additional capacity for GLP-1 products such as Novo’s Ozempic (semaglutide). Novo Nordisk first launched the GLP-1 therapy Semaglutide, in the US in December 2017, under the brand name Ozempic. The drug has since been approved in the US, Canada, EU, Japan, and Australia as a treatment for T2D. Novo Nordisk later launched the therapy under the name Wegovy for the treatment of weight loss, together with diet and physical activity. Novo Nordisk is a ...
- Source: drugdu
- 100
- November 28, 2023
Health Canada approves Jazz’s cannabis derived seizure therapy

Health Canada has approved Jazz Pharmaceuticals’s Epidiolex (cannabidiol oral solution) as an adjunct therapy in patients aged two years and older for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, and tuberous sclerosis complex (TSC). Epidiolex is a plant-based oral cannabidiol solution. It was developed by GW Pharmaceuticals and was added to Jazz’s portfolio following GW’s acquisition in 2021. The therapy was first approved in the US as an adjunct therapy in patients aged two years and older for the treatment of seizures associated with LGS and Dravet syndrome in June 2018. The approval in TSC came in July 2020. All three indications causes different types of serizure. LGS and Dravet syndrome are types of epileptic encephalopathy, that cause seizures. LGS is managed by two or more seizure medications whilst Dravet is treatment-resistant. TCS is a rare genetic condition that causes benign tumours to develop in different ...
- Source: drugdu
- 98
- November 28, 2023
Surge in respiratory illnesses reported in China

Chinese authorities from the National Health Commission have reported an increase in incidence of respiratory diseases in China. This increase has been attributed to the lifting of COVID-19 restrictions and the circulation of known pathogens such as influenza, Mycoplasma pneumoniae, respiratory syncytial virus (RSV), and COVID-19. These are all common pathogens but due to changes in social mixing may not follow usual seasonal infection patterns. The UK experienced similar trends in 2022. The World Health Organization (WHO) provided an update on 23 November after speaking with Chinese health authorities from the Chinese Center for Disease Control and Prevention and the Beijing Children’s Hospital. The Chinese authorities advised that there has been no detection of any unusual or novel pathogens or unusual clinical presentations, including in Beijing and Liaoning, but only the general increase in respiratory illnesses due to multiple known pathogens. UKHSA is closely monitoring the situation and will respond ...
- Source: drugdu
- 106
- November 27, 2023
BD hires new chief medical officer from 3M Health Care

BY JIM HAMMERAND Dr. Ron Silverman is the next chief medical officer of Becton, Dickinson & Co. [Photo courtesy of BD] Becton, Dickinson & Co. (NYSE: BDX)+ today named Dr. Ronald “Ron” Silverman as EVP and chief medical officer. He replaces BD Chief Medical Officer Dr. William Sigmund, who announced plans to retire from BD earlier this year. The change takes effect Dec. 4, 2023. Silverman comes from 3M Health Care, where he served as SVP and chief medical officer since 2021. He will lead BD’s medical affairs organization across BD’s business units, regions and central team. Franklin Lakes, New Jersey-based BD said Silverman “will use medical insights and expertise to advance BD’s pipeline of clinically relevant, innovative solutions that align with evolving patient needs, while also contributing to the safety and compliance of BD’s in-market portfolio of products.” Silverman will report to BD EVP and Chief Technology Officer Beth ...
- Source: drugdu
- 92
- November 27, 2023
White Bagging Policies Endanger the Lives of Cancer Patients

Insurers and PBMs are increasingly implementing white-bagging policies, which require oncology practices to obtain physician-administered infusions and other medications from designated specialty pharmacies often owned by or affiliated with insurers and their PBMs. By DR. JAMAL MISLEH Earlier this year, a young man in his mid-thirties with non-Hodgkin’s Lymphoma came to my oncology clinic for a chemotherapy infusion while waiting on the development of his CAR-T treatment. Under normal circumstances, our practice can move quickly when scheduling patients for their treatments since our in-office infusion clinic maintains an inventory of necessary medications that we prepare ourselves onsite. But, unbeknownst to me, my patient’s health insurance plan included a policy called “white bagging,”- a policy which we soon discovered when they denied one of the chemotherapy drugs I prescribed. Our clinical team repeatedly appealed the denial; however, the plan refused to cover the drug unless it was fulfilled through an unspecified ...
- Source: drugdu
- 95
- November 27, 2023
report

After many months of shortages affecting attention-deficit/hyperactivity disorder (ADHD) drugs, it was hoped that new generics to Takeda’s Vyvanse would ease the supply situation. But according to a letter from the Association for Accessible Medicines (AAM), production limits on the drug’s active ingredient—set by the government—are at least partly to blame for the shortage that has spread to the generics. Generic drugmakers haven’t been able to obtain enough raw material to “launch their products at full commercial scale,” AAM wrote to the Drug Enforcement Administration (DEA), according to Bloomberg. The DEA sets specific restrictions on production to avoid an excess of supply that could spread to the black market due to Vyvanse’s status as a controlled substance. The agency sets its limits based on past production levels and future sales commitments, which poses a problem given that some companies are cleared to launch the generics but haven’t sold any so ...
- Source: drugdu
- 248
- November 26, 2023
FDA fast tracks Alladapt’s multi-food allergy immunotherapy

The US Food and Drug Administration (FDA) has granted a fast track designation to Alladapt Immunotherapeutics’ IgE-mediated multi-food oral immunotherapy ADP101. The FDA’s decision was based on the results from the Phase I/II Harmony trial, which investigated the immunotherapy’s use in inducing desensitisation in patients with single or multiple food allergies, including nuts, dairy, seafood and more. Fast track designations enable earlier interactions with the FDA for the pursuit of accelerated approval. The status also opens chances of rolling and priority reviews. In this instance the designation allows Alladapt to seek accelerated approval for oral immunotherapy in paediatric patients, aged between four and 17 years, with one or more of the 15 food allergies covered by ADP101, as per a 22 November press release. Phase I/II data The double-blind, placebo-controlled Phase I/II Harmony trial (NCT04856865) enrolled 61 paediatric patients (aged four-17 years) and 12 adult patients (aged 18-55 years). The ...
- Source: drugdu
- 209
- November 26, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.